Unicycive Therapeutics reported a net loss of $1.7 million, or $0.06 per share, for the second quarter ended June 30, 2026, compared to a $6.5 million loss in the prior year period, driven by a $8.4 million gain from the change in fair value of its warrant liability. The company holds $61.4 million in cash and marketable securities as of June 30, 2026, providing expected runway into 2027. Operationally, Unicycive received a Complete Response Letter for its New Drug Application for oxylanthanum carbonate due to manufacturing deficiencies at a third-party vendor; however, the FDA has now assigned an inspection to this facility, which is a prerequisite for resubmitting the application. The company continues commercial readiness initiatives while awaiting inspection results. Unicycive Therapeutics operates in the biotechnology industry, developing therapies for kidney diseases.

Unicycive Therapeutics reported an ending cash balance of approximately $61.4 million as of June 30, 2026, based on preliminary unaudited second-quarter results. The company operates in the biotechnology industry and develops therapeutic products.